Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Gemini Pharmaceuticals' private label products are formulated to be as effective as their name-brand twins. The company makes prescription and OTC pharmaceuticals and nutritional supplements, including acetaminophen, vitamin B-12, and herbal enhancers. Its pharmaceutical offerings include cough and cold medications, pain relievers, and sleeping aids. Its supplement product line starts with such basics as vitamins and minerals, and then includes what it calls "specialty products" such as energy boosters and weight loss supplements. Gemini Pharmaceuticals also makes pet care supplements such as joint support and allergy relief and prescription prenatal vitamins and other custom formulations.

CyBio just might supplant the underpaid laboratory research assistant, so efficient are its automated systems; in all, the company makes it easier for laboratory scientists to focus on research and less on the repetitive processes involved therein. CyBio develops, produces, and markets technology platforms for drug discovery. With more than 15 years of experience in the field, CyBio provides the tools for pharmaceutical and agrochemical research, including pipetting instruments for liquid handling, incubating, and replicating, as well as software and system integration, for automated screening and reading.

ARIUS Research Inc. company was founded in 1999 and is based in Toronto, Canada. As of September 23, 2008, Arius Research Inc. operates as a subsidiary of Roche Holding AG. ARIUS Research, Inc., a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform, FunctionFIRST. The company’s product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. ARIUS has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Inc., Medarex, Inc., Genentech, Inc., and Takeda Pharmaceutical Company Limited.

454 Life Sciences company has developed a computer-controlled instrument and related software that enable scientists to analyze whole genomes in one fell swoop, rather than a few hundred genes at a time. Parent company Roche Diagnostics distributes 454 Life Sciences' Genome Sequencing Systems to clinical laboratories, research departments of drugmakers, and other customers worldwide. Research fields include cancer and infectious disease, drug discovery, and paleontology. The company's 454 Sequencing Center provides sequencing services directly.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Sinovac Biotech Ltd. is a profitable biopharmaceutical company headquartered in Beijing, China. The Company focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases including hepatitis A, seasonal influenza, H5N1 (bird flu) pandemic influenza and H1N1 influenza. Sinovac received approval in 2009 for its H1N1 influenza vaccine, PANFLU.1 and has commenced fulfilling orders from the Chinese Central Government pursuit to the government stockpiling program. Sinovac was the first company worldwide to receive approval for H1N1 influenza vaccine.

Cornerstone Therapeutics Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for the respiratory market in the United States. Its marketed products include SPECTRACEF for the treatment of mild to moderate infections, such as community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis and tonsillitis, and uncomplicated skin and skin-structure infections; ZYFLO CR for the prevention and chronic treatment of asthma in adults and children 12 years of age or older; and ALLERX Dose Pack products, which are oral tablets for the temporary relief of symptoms associated with allergic rhinitis.Cornerstone Therapeutics company also markets HYOMAX line of products, which consist of generic formulations of four antispasmodic medications containing the API hyoscyamine sulfate, an anticholinergic for functional intestinal disorders to reduce symptoms, such as those seen in mild dysenteries and diverticulitis; and BALACET 325, APAP 325, and APAP 500 for the relief of mild to moderate pain. In addition, its products under development include SPECTRACEF Once Daily for acute bacterial exacerbations of chronic bronchitis with COPD; SPECTRACEF Suspension for pharyngitis and tonsillitis, and acute otitis media; CRTX 058 for temporary relief of symptoms associated with allergic rhinitis; and CRTX 067 and CRTX 069 for temporary relief of symptoms associated with cough, and upper respiratory symptoms associated with allergies or a cold.

Paddock Laboratories, Inc. company was founded in 1977 by Chairman Bruce Paddock. Paddock Laboratories, Inc. company develops and manufactures bioequivalent generic pharmaceuticals and OTC specialty products. Paddock's product line includes suppositories, diabetes treatments, topical powders, enemas, injectables, and dermatological offerings, as well as compounding bases and charcoal products. Its manufacturing facilities are located in Minneapolis, Minnesota. In addition to the US market, some of Paddock's products are sold in Europe and the Asia/Pacific region through distributors.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.